Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Download Vara einkenni (SPC)
17-12-2021
Download Opinber matsskýrsla (PAR)
31-08-2021

Virkt innihaldsefni:

lenalidomide hydrochloride monohydrate

Fáanlegur frá:

Krka, d.d., Novo mesto 

ATC númer:

L04AX04

INN (Alþjóðlegt nafn):

lenalidomide

Meðferðarhópur:

Immunosuppressants

Lækningarsvæði:

Multiple Myeloma; Lymphoma, Follicular

Ábendingar:

Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Vörulýsing:

Revision: 3

Leyfisstaða:

Authorised

Leyfisdagur:

2021-02-11

Upplýsingar fylgiseðill

                                79
B. PACKAGE LEAFLET
80
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LENALIDOMIDE KRKA D.D. NOVO MESTO 2.5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 7.5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 10 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 15 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 20 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 25 MG HARD CAPSULES
lenalidomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lenalidomide Krka d.d. Novo mesto is and what it is used for
2.
What you need to know before you take Lenalidomide Krka d.d. Novo
mesto
3.
How to take Lenalidomide Krka d.d. Novo mesto
4.
Possible side effects
5.
How to store Lenalidomide Krka d.d. Novo mesto
6.
Contents of the pack and other information
1.
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS AND WHAT IT IS USED FOR
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS
Lenalidomide Krka d.d. Novo mesto contains the active substance
‘lenalidomide’. This medicine
belongs to a group of medicines which affect how your immune system
works.
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS USED FOR
Lenalidomide Krka d.d. Novo mesto is used in adults for:
-
Multiple myeloma
-
Follicular lymphoma
MULTIPLE MYELOMA
Multiple myeloma is a type of cancer which affects a certain kind of
white blood cell, called the
plasma cell. These cells collect in the bone marrow and divide,
becoming out of control. This can
damage the bones and kidneys.
Multiple myeloma generally c
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 25 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard capsule contains lenalidomide hydrochloride monohydrate
equivalent to 2.5 mg, 5 mg,
7.5 mg, 10 mg, 15 mg, 20 mg or 25 mg lenalidomide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule (capsule)
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules
Capsule cap is green, capsule body is green with imprinted black mark
2.5. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 4, length 14
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules
Capsule cap is blue, capsule body is blue with imprinted black mark 5.
Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 2, length 18
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules
Capsule cap is brown, capsule body is brown with imprinted white mark
7.5. Capsule content is white
to yellow white or to brown white powder. Hard capsule size: 1, length
19 ± 1 mm.
Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules
Capsule cap is green, capsule body is brown with imprinted white mark
10. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 0, length 21
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules
Capsule cap is brown, capsule body is blue with imprinted black mark
15. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 2, length 18
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules
Capsule cap is green, capsule body is blue with imprinted black mark
20
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 17-12-2021
Vara einkenni Vara einkenni búlgarska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla búlgarska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 17-12-2021
Vara einkenni Vara einkenni spænska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla spænska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 17-12-2021
Vara einkenni Vara einkenni tékkneska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla tékkneska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 17-12-2021
Vara einkenni Vara einkenni danska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla danska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 17-12-2021
Vara einkenni Vara einkenni þýska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla þýska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 17-12-2021
Vara einkenni Vara einkenni eistneska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla eistneska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 17-12-2021
Vara einkenni Vara einkenni gríska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla gríska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 17-12-2021
Vara einkenni Vara einkenni franska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla franska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 17-12-2021
Vara einkenni Vara einkenni ítalska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla ítalska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 17-12-2021
Vara einkenni Vara einkenni lettneska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla lettneska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 17-12-2021
Vara einkenni Vara einkenni litháíska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla litháíska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 17-12-2021
Vara einkenni Vara einkenni ungverska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla ungverska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 17-12-2021
Vara einkenni Vara einkenni maltneska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla maltneska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 17-12-2021
Vara einkenni Vara einkenni hollenska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla hollenska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 17-12-2021
Vara einkenni Vara einkenni pólska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla pólska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 17-12-2021
Vara einkenni Vara einkenni portúgalska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla portúgalska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 17-12-2021
Vara einkenni Vara einkenni rúmenska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla rúmenska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 17-12-2021
Vara einkenni Vara einkenni slóvakíska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 17-12-2021
Vara einkenni Vara einkenni slóvenska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla slóvenska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 17-12-2021
Vara einkenni Vara einkenni finnska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla finnska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 17-12-2021
Vara einkenni Vara einkenni sænska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla sænska 31-08-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 17-12-2021
Vara einkenni Vara einkenni norska 17-12-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 17-12-2021
Vara einkenni Vara einkenni íslenska 17-12-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 17-12-2021
Vara einkenni Vara einkenni króatíska 17-12-2021
Opinber matsskýrsla Opinber matsskýrsla króatíska 31-08-2021

Leitaðu viðvaranir sem tengjast þessari vöru